Merck: FDA reviewing tablet to eliminate allergy
Drugmaker Merck & Co. says federal regulators are reviewing its application to sell a new type of treatment for grass pollen allergy that reduces symptoms over time, rather than just temporarily relieving the sneezing and itching.
The treatment, a tablet that dissolves under the tongue, could become the first alternative available in the United States to a long series of uncomfortable allergy shots. Both methods work by gradually desensitizing the patient's immune system to the substance triggering the allergic reaction. Merck's immunotherapy, still unnamed, would be taken daily throughout allergy season.
for three years.
The company, which is based in Whitehouse Station, N.J., also recently applied to the Food and Drug Administration for approval to sell an immunotherapy tablet for ragweed pollen.
Show commenting policy
TribLive commenting policy
You are solely responsible for your comments and by using TribLive.com you agree to our Terms of Service.
We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.
While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.
We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers.
We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.
We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.
We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.
We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.
- Alcoa supplying parts for military jets under $1.1B pact with Lockheed Martin
- Rice, Gulfport team on Utica shale pipeline system
- Renewed Anheuser-Busch InBev bid for SABMiller ups stake in beer battle
- Bear sharpens claws on ‘old Pittsburgh’
- Consumers bureau targets mandatory arbitration
- Energy efficiency goes mainstream with help of regulations, demand
- Google is latest tech giant to claim space in mobile news
- Power plants challenged by carbon capture and storage
- Eat’n Park sells Cura division that serves hospitals and senior living
- Credit bureau Experian keeps info on cellular firm’s customers
- AB InBev ups its offer for SABMiller to create beer giant